<DOC>
	<DOCNO>NCT02196831</DOCNO>
	<brief_summary>Liver disease one lead co-morbidities human immunodeficiency virus ( HIV ) infection , nonalcoholic fatty liver disease ( NAFLD ) present approximately 30-40 % patient HIV infection . Nonalcoholic steatohepatitis ( NASH ) severe form NAFLD increase liver fat also accompany inflammation , cellular damage , fibrosis . NAFLD prevalent patient also increase visceral adiposity , group previously show HIV-infected individual increase visceral adiposity generally decrease growth hormone secretion . Tesamorelin growth hormone release hormone ( GHRH ) analogue increase endogenous growth hormone secretion . Tesamorelin FDA-approved reduction visceral fat HIV-infected individual . In previous study , treatment tesamorelin HIV-infected individual select abdominal adiposity reduce liver fat . The current study design test effect tesamorelin liver fat steatohepatitis HIV-infected individual NAFLD . The investigator hypothesize tesamorelin reduce liver fat also ameliorate inflammation , fibrosis , hepatocellular damage see conjunction NASH .</brief_summary>
	<brief_title>Tesamorelin Effects Liver Fat Histology HIV</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
	<criteria>Inclusion criterion : Men woman 1870yo HIVinfection treatment stable antiretroviral regimen ≥ 6 month Hepatic steatosis demonstrate liver fat fraction ≥5 % 1HMRS Hepatitis C antibody negative , , Hepatitis C antibody positive , either : ) know clinical disease , successful therapy ≥1 year prior baseline undetectable HCV RNA , b ) HCV resolve spontaneously undetectable HCV RNA . Hepatitis B surface antigen negative screen visit For female ≥50yo , negative mammogram within 1 year baseline visit If use Vitamin E ≥400 IU daily ( formulation ) , stable dose ≥6 month prior study . Exclusion criterion : Heavy alcohol use define consumption 20g daily woman 30g daily men least 3 consecutive month past 5 year Use insulin thiazoledinediones ( TZDs ) , HbA1c ≥7 % . Individuals mild diabetes wellcontrolled diet and/or oral antidiabetic agent besides TZDs include . Use oral antidiabetic must stable ≥6 month prior study entry . Known diabetic retinopathy . Known cirrhosis , ChildPugh score ≥7 , stage 4 fibrosis biopsy , clinical evidence cirrhosis portal hypertension image exam . Chronic corticosteroid use except intermittent use topical steroid cream and/or prior shortterm physiologic corticosteroid use ≤ 6 month prior baseline visit Chronic use methotrexate , amiodarone , tamoxifen Known diagnosis Alpha1 antitrypsin deficiency , Wilson 's disease , hemochromatosis , autoimmune hepatitis Use GH GHRH within past 1 year Change lipid lower antihypertensive regimen within 3 month screen HgB &lt; 11.0 g/dL , CD4 &lt; 100 th/mm3 , HIV viral load &gt; 400 copies/mL Active malignancy For men , history prostate cancer evidence prostate malignancy PSA &gt; 5 ng/mL Severe chronic illness judge investigator present contraindication participation History hypopituitarism , head irradiation condition know affect GH axis Use physiologic testosterone ( men ) estrogen progesterone ( woman ) unless stable use year prior study entry Routine MRI exclusion criterion presence pacemaker cerebral aneurysm clip Previous weight loss surgery For woman , positive pregnancy test perform CLIA certify laboratory use test sensitivity least 25mIU/mL , breastfeed . Known hypersensitivity tesamorelin mannitol Unwillingness abstain conception process study ( i.e. , must agree participate active attempt become pregnant impregnate , donate sperm , participate vitro fertilization ) Unwillingness use one ( male ) two ( female ) reliable method contraception engage heterosexual intercourse study . Acceptable method woman include hormonal contraception ( estrogen/progesterone progesteroneonly formulation ) stable year prior study entry , intrauterine device , barrier method ( condom , diaphragm spermicide ) . Acceptable method male include condom use . This requirement apply woman postmenopausal least 24 consecutive month undergone surgical sterilization , men undergo surgical sterilization document azoospermia . Not willing able adhere dose schedule require procedure per protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Human immunodeficiency virus ( HIV )</keyword>
	<keyword>Nonalcoholic fatty liver disease ( NAFLD )</keyword>
	<keyword>Nonalcoholic steatohepatitis ( NASH )</keyword>
	<keyword>Growth hormone release hormone</keyword>
	<keyword>tesamorelin</keyword>
</DOC>